platinum has been researched along with pemetrexed in 99 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (4.04) | 29.6817 |
| 2010's | 44 (44.44) | 24.3611 |
| 2020's | 51 (51.52) | 2.80 |
| Authors | Studies |
|---|---|
| Belani, C; Ramalingam, S | 1 |
| Ciuleanu, T; Darstein, CL; Latz, JE; Musib, LC; Specenier, PM; Vermorken, JB | 1 |
| Dickgreber, NJ; Fink, TH; Hossain, AM; Latz, JE; Musib, LC; Thomas, M | 1 |
| Chen, ZW; Lu, S; Zhang, YF | 1 |
| Berard, H; Bota, S; Chouaid, C; Corre, R; Crequit, J; Dujon, C; Paillotin, D; Robinet, G; Thomas, P; Vergnenegre, A | 1 |
| Jiang, J; Li, L; Lin, Q; Tian, J; Wang, Q; Wang, X | 1 |
| Fan, Y; Huang, ZY; Luo, LH; Yu, HF | 1 |
| Bergot, E; Lechapt, E; Zalcman, G | 1 |
| Bennouna, J; de Castro, J; Dingemans, AM; Gridelli, C; Griesinger, F; Grossi, F; Langer, C; Rossi, A; Thatcher, N; Wong, EK | 1 |
| Saijo, N | 1 |
| An, TT; Bai, H; Duan, JC; Liu, XH; Wang, J; Wang, SH; Wang, YY; Wang, ZJ; Wu, MN; Yang, L; Zhao, J; Zhuo, ML | 1 |
| He, J; Li, H; Lu, J; Ma, P; Qin, Y; Wang, J; Wei, L; Xu, J; Zhang, X | 1 |
| Amundsen, T; Anderssen, E; Dobra, K; Erlandsen, SE; Flatberg, A; Røe, OD; Sandeck, H; Sundstrøm, SH; Szulkin, A | 1 |
| Hashemi-Sadraei, N; Pennell, NA | 1 |
| Barrington, S; Cane, P; Dunn, JT; Lal, R; Landau, D; Lang-Lazdunski, L; McLennan, B; Papa, S; Popat, S; Prevost, AT; Shah, R; Spicer, J; Viney, Z | 1 |
| Akca, Z; Aksahin, A; Aslan, T; Berk, V; Buyukcelik, A; Erden, A; Karaca, H; Mutlu, H; Ozkan, M | 1 |
| Eaddy, M; Green, MR; Gruschkus, SK; Peterson, P; Shah, M; Winfree, KB | 1 |
| Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; Xiang, J; Xu, L; Xu, X | 1 |
| Hao, X; He, P; Hu, X; Li, J; Shi, Y; Wang, B; Wang, H; Wang, Y; Wang, Z; Yang, S; Yu, S; Zhang, X | 1 |
| Dyszkiewicz, W; Kalinka-Warzocha, E; Kałakucka, K; Knetki-Wróblewska, M; Kowalski, DM; Krawczyk, P; Krzakowski, M; Kucharczyk, T; Milanowski, J; Powrózek, T; Ramlau, R; Winiarczyk, K; Wojas-Krawczyk, K | 1 |
| Georgoulias, V; Giagkas, G; Ioannidis, G; Koutsopoulos, A; Lagoudaki, E; Mavroudis, D; Papadaki, C; Sfakianaki, M; Souglakos, J; Trypaki, M; Tsakalaki, E; Voutsina, A | 1 |
| Dyszkiewicz, W; Kalinka-Warzocha, E; Knetki-Wróblewska, M; Kowalski, DM; Krawczyk, P; Krzakowski, M; Kucharczyk, T; Milanowski, J; Powrózek, T; Ramlau, R; Winiarczyk, K | 1 |
| Chen, Q; Ding, L; Gao, H; Hong, X; Jiang, Z; Liang, Y; Liu, K; Wu, H; Zhou, N | 1 |
| Heo, DS; Keam, B; Kim, DW; Kim, JS; Kim, KH; Kim, SH; Kim, TM; Kim, YJ; Lee, JS; Lee, SH; Park, S | 1 |
| Apollo, A; Bajorin, DF; Bambury, RM; Benjamin, DJ; Chaim, JL; Garcia-Grossman, IR; Iyer, G; Ostrovnaya, I; Regazzi, AM; Rosenberg, JE; Sullivan, J; Voss, MH; Xiao, H; Zabor, EC | 1 |
| Chen, YM; Lee, YC; Lin, YH; Perng, RP; Tseng, YC; Tseng, YH; Whang-Peng, J | 1 |
| Barker, SS; Borghaei, H; Obasaju, C; Stinchcombe, TE; Treat, JA | 1 |
| Felley-Bosco, E; Friess, M; Frischknecht, L; Korol, D; Opitz, I; Soltermann, A; Stahel, R; Thies, S; Vrugt, B; Weder, W | 1 |
| Hsiue, TR; Hwang, JS; Lai, WW; Lin, CK; Su, WC; Wang, JD; Yang, SC | 1 |
| Huo, Z; Jiang, SY; Wang, MZ; Xu, Y; Zhang, J; Zhao, J; Zhong, W | 1 |
| Ahn, M-J; Akamatsu, H; Garassino, MC; Ghiorghiu, S; He, Y; Kim, HR; Lee, CK; Mann, H; Marotti, M; Mok, TS; Papadimitrakopoulou, VA; Ramalingam, SS; Sebastian, M; Shepherd, FA; Templeton, A; Theelen, WS; Wu, Y-L | 1 |
| Antonio, BS; Bunn, PA; Ciuleanu, T; Denne, J; Iturria, N; John, W; Paz-Ares, LG; Scagliotti, GV; Zimmermann, A | 1 |
| Pinion, S | 1 |
| Li, J; Liu, Y; Wang, Z; Yang, L; Zhai, X; Zheng, Q; Zhu, Y | 1 |
| Gao, H; He, K; Li, L; Li, X; Liu, X; Qin, H; Qu, L; Tang, C; Wang, L; Wang, W; Xu, B; Yang, L | 1 |
| Ren, X; Wang, J; Wei, F; Xiong, Y; Zhao, N; Zheng, Y | 1 |
| Agarwal, JP; Bhargava, P; Janu, A; Joshi, A; Kapoor, A; Mahajan, A; Noronha, V; Patil, VM; Prabhash, K; Zanwar, S | 1 |
| Pan, Z; Shen, Q; Shen, Y; Sun, K; Wang, Y; Zhang, X; Zhang, Z; Zhao, J; Zheng, J; Zhou, J; Zhu, Y | 1 |
| Akamatsu, H; Hida, T; Hodge, RA; Imamura, F; Katakami, N; Kato, T; Kim, YH; Okamoto, I; Shinkai, M; Uchida, H | 1 |
| Wang, Y; Xu, F; Xu, H; Ying, J; Zhu, W | 1 |
| Ardito, R; Barni, S; Borgonovo, K; Cabiddu, M; Coinu, A; Conti, B; Ghidini, A; Ghilardi, M; Petrelli, F | 1 |
| Gandhi, L | 1 |
| Akamatsu, H; Chang, GC; Delmonte, A; Huang, X; Jenkins, S; John, T; Lee, JS; Su, WC; Wu, YL | 1 |
| Dowell, JE; Gerber, DE; McGehee, E; Reisch, J | 1 |
| Archila, P; Arrieta, O; Bacon, L; Báez, R; Campos Gómez, S; Cardona, AF; Carranza, H; Chirinos, L; Corrales, L; Cuello, M; de Lima, VCC; Freitas, HC; González, L; Granados, ST; Karachaliou, N; Martín, C; Mas, L; Núñez Cerrillo, G; Oblitas, G; Otero, J; Pérez, MA; Ramírez-Tirado, LA; Remolina Bonilla, YA; Rodriguez, J; Rojas, L; Rosell, R; Ruiz-Patiño, A; Trejo-Rosales, R; Vargas, C; Zatarain-Barrón, ZL | 1 |
| Aasheim, LB; Abrahamsen, TW; Davidson, B; Dybdahl, B; Flatmark, K; Fromm, B; Hovig, E; Julsrud, L; Kristensen, AT; Larsen, SG; Lund-Andersen, C; Nakken, S; Nygård, S | 1 |
| Li, B; Li, P; Li, X; Shen, S; Shi, Y; Zhang, F | 1 |
| Germonpré, P; Van den Wyngaert, T | 1 |
| Baglivo, S; Bellezza, G; Brambilla, M; Chiari, R; Cortellini, A; Crinò, L; De Giglio, A; Ficorella, C; Ludovini, V; Metro, G; Ricciuti, B; Sidoni, A | 1 |
| Chin, E; Dagogo-Jack, I; Digumarthy, SR; Gainor, JF; Lin, JJ; Ou, SI; Plodkowski, AJ; Riely, GJ; Rooney, M; Schoenfeld, AJ; Shaw, AT; Yeap, BY; Zhu, VW | 1 |
| Ishiki, H; Kiuchi, D; Kubo, E; Satomi, E; Shimizu, M; Tanaka, T; Yokota, S | 1 |
| Chen, CY; Chen, KY; Shih, JY; Yu, CJ | 1 |
| Bas, T; Bischoff, HG; Boyer, M; Cheng, SY; Clingan, P; Dómine, M; Esteban, E; Felip, E; Gadgeel, S; Garassino, MC; Garon, EB; Gray, JE; Grossi, F; Hochmair, MJ; Hui, R; Jennens, RR; Kurata, T; Novello, S; Peled, N; Pietanza, MC; Powell, SF; Reck, M; Rodríguez-Abreu, D; Rubio-Viqueira, B; Speranza, G; Yang, J | 1 |
| Si, X; Wang, H; Wang, M; You, Y; Zhang, L; Zhang, X | 1 |
| Chu, TQ; Han, BH; Lou, YQ; Xu, JL; Zhong, H; Zhong, RB | 1 |
| Jiang, Y; Wang, X | 1 |
| Cheng, Y; Cui, J; Leaw, SJ; Liu, Z; Ma, X; Ma, Y; Ma, Z; Shu, Y; Tan, W; Wang, J; Wang, Z; Wu, Y; Zhang, Y; Zhao, J | 1 |
| Bi, M; Cang, S; Chen, G; Cheng, Y; Fang, J; Feng, J; Han, B; He, Z; Li, B; Li, J; Li, W; Lu, Y; Ma, R; Mei, X; Ren, X; Song, Y; Wang, L; Wang, S; Wang, Y; Wang, Z; Xie, C; Yang, N; Yang, Y; Yang, Z; Yu, Q; Yu, Z; Zhang, L; Zhang, W; Zhang, Y; Zhao, Y; Zhou, H; Zhou, J; Zhou, R; Zhu, D | 1 |
| Ahn, MJ; Akamatsu, H; Delmonte, A; Han, JY; He, Y; John, T; Kim, SW; Laskin, J; Laus, G; Mann, H; Miranda, M; Mok, TS; Papadimitrakopoulou, VA; Ramalingam, SS; Rukazenkov, Y; Sebastian, M; Shepherd, FA; Su, WC; Theelen, WSME; Wu, YL | 1 |
| Forde, PM; Lam, VK | 1 |
| Doi, H; Ishigaki, H; Kijima, T; Kitajima, K; Koda, Y; Kuribayashi, K; Minami, T; Nakajima, Y; Nakamura, A; Takahashi, R; Yokoi, T | 1 |
| Asahina, H; Isobe, T; Kagamu, H; Kikuchi, T; Kobayashi, K; Maemondo, M; Morita, S; Oizumi, S; Okamoto, I; Seike, M; Sugio, K; Takahashi, K; Tanaka, K | 1 |
| Cui, L; Jiao, X; Zhang, Z; Zhao, N | 1 |
| Yang, Y; Zhang, L; Zhou, H | 1 |
| Aerts, J; Gadgeel, SM; Garon, EB; Kim, JS; Muehlenbein, CE; Peterson, P; Rizzo, MT | 1 |
| Bearz, A; De Carlo, E; Del Conte, A; Schiappacassi, M; Stanzione, B | 1 |
| Aomori, T; Arami, T; Egami, S; Fukunaga, K; Hashimoto, H; Ikemura, S; Kawada, I; Kawazoe, H; Nakada, H; Nakamura, T; Ohe, Y; Sakiyama, N; Soejima, K; Uozumi, R; Yamaguchi, M; Yasuda, H | 1 |
| Bi, M; Cang, S; Chen, G; Fang, J; Fang, W; Feng, J; Han, B; He, Z; Li, B; Li, J; Li, W; Lu, Y; Ma, R; Mancao, C; Mei, X; Peng, B; Puig, O; Ren, X; Song, Y; Sun, J; Sun, L; Wang, S; Wang, Z; Xu, W; Yang, Y; Yang, Z; Yu, Q; Zhang, L; Zhou, H; Zhou, J; Zhou, R | 1 |
| Chang, GR; Chen, CM; Chen, W; Chong, KY; Cidem, A; Lin, CH; Staniczek, T; Tsai, YT; Wang, JL; Yen, CC | 1 |
| Avancini, A; Belluomini, L; Casali, M; Dionisi, V; Mazzarotto, R; Menis, J; Milella, M; Palmerio, S; Pilotto, S; Riva, ST; Vincenzi, S | 1 |
| Danese, MD; Daumont, M; Gleeson, M; Lubeck, D; Nwokeji, E; Penrod, JR | 1 |
| Sharma, S; Singh, N; Walia, HK | 1 |
| Bajor, DL; Biswas, T; Bruno, DS; Cao, S; Dowlati, A; Fu, P; Gerson, SL; Kunos, CA; Machtay, M; Malik, S; Oleinick, NL; Patel, M; Pink, JJ | 1 |
| Garon, EB; Kim, JS; Peterson, P; Rizzo, MT | 1 |
| Duan, J; Jiang, Z; Zeng, X | 1 |
| Tian, H; Tian, Y; Yu, J; Zhai, X; Zhu, H | 1 |
| An, T; Chen, H; Chi, Y; Huang, D; Jia, B; Li, J; Lin, G; Wang, J; Wang, Y; Wang, Z; Wu, M; Yang, X; Zhai, X; Zhao, J; Zhuo, M | 1 |
| Cheong, TF; Chiang, KY; Ho, JCM; Ip, MSM; Kwok, WC; Lam, DCL; Tam, TCC | 1 |
| Asghari, AB; Chai, SM; Creaney, J; Dick, IM; Firth, T; Hansen, J; Lee, YCG; Louw, A; Lynggaard, LA; Meristoudis, C; Panou, V; Røe, OD; Szejniuk, WM; van Vliet, C; Vyberg, M | 1 |
| Gu, X; Lou, G; Shao, L; Shi, Z; Song, Z; Wang, W; Zhang, Y | 1 |
| Aa, L; Gao, J; Jiang, W; Li, W; Liang, J; Sun, W; Wang, H; Wang, L; Zhou, W | 1 |
| Ma, J; Zhang, S | 1 |
| Gu, Q; Li, S | 1 |
| Chen, Z; Ke, Y; Lin, Z; Lu, Z; Rao, D; Sun, T; Wu, S; Ye, M; Zhang, D; Zhang, X | 1 |
| Fathallah, H; Karim, NA; Morris, JC; Pathrose, P; Perry, A; Starnes, SL; Ullah, A; Wang, J | 1 |
| Cang, S; Chen, G; Fang, J; Han, B; Lin, Y; Mei, X; Stefaniak, V; Sun, L; Wang, S; Wang, Z; Yang, Y; Yang, Z; Yu, Q; Zhang, L; Zhang, W | 1 |
| Cao, L; Fan, Y; Fang, J; He, J; Hu, J; Liu, W; Liu, Y; Lu, S; Shi, J; Wang, Z; Xia, J; Yi, J; Zhou, J | 1 |
| Dunne, B; Harden, S; Hoang, W; John, T; Leal, JL; Xue, J | 1 |
| Gao, Y; Li, B; Liu, Y; Wang, Y; Zhang, T; Zhang, Z; Zhao, C | 1 |
| Belletti, M; Bono, F; Bonomi, M; Canova, S; Carlucci, L; Ceresoli, GL; Cortinovis, DL; D'Aveni, A; De Angelis, A; De Simone, I; Galli, F; Gelsomino, F; Grosso, F; Mencoboni, M; Pasello, G; Perrino, M; Rulli, E; Zucali, PA | 1 |
| Baglivo, S; Bellezza, G; Bonaiti, A; Colafigli, C; Di Girolamo, B; Ludovini, V; Mandarano, M; Matocci, R; Metelli, N; Metro, G; Roila, F | 1 |
| Aggarwal, H; Muehlenbein, CE; Ndirangu, K; Thom, H; Tongbram, V; Winfree, KB; Zhu, E | 1 |
| Abo Elkasem, F; Bahnassy, A; Gaafer, R; Khorshid, O; Wahba, NI | 1 |
| Bigay-Game, L; Bylicki, O; Castera, M; Chouaid, C; Clarisse, B; Daniel, C; Decroisette, C; Doubre, H; Geier, M; Greillier, L; Grellard, JM; Guisier, F; Martins-Lavinas, PH; Monnet, I; Moreau, D; Peloni, JM; Radj, G; Ricordel, C; Subtil, F; Swalduz, A; Toffart, AC; Tomasini, P | 1 |
| Bleckmann, A; Frost, N; Griesinger, F; Grohé, C; Janning, M; Kollmeier, J; Reck, M; Reinmuth, N; Sebastian, M; Thomas, M | 1 |
| Beebe, KD; Conroy, JM; Davison, JM; Eisner, JR; Farhangfar, C; Farhangfar, F; Guo, Y; Hayes, DN; Mayhew, GM; Milburn, MV; Mileham, KF; Shibata, Y; Uronis, JM | 1 |
| Barbier, MC; Bhadhuri, A; Fengler, A; Gautschi, O; Meier, N; Pardo, E | 1 |
| Goto, Y; Gyotoku, H; Harada, D; Kogure, Y; Murakami, S; Ninomiya, K; Nomura, S; Okamoto, H; Okishio, K; Okuma, Y | 1 |
| Cedrés, S; Hansen, TB; Herrera-Juarez, M; Isambert, N; Jaderberg, M; Lederlin, M; Levitsky, V; Martinez-Marti, A; Navarro, A; Paz-Ares, L; Ponce, S; Ricordel, C; Serres, X; Vetrhus, S; Viteri, S; Zugazagoitia, J | 1 |
12 review(s) available for platinum and pemetrexed
| Article | Year |
|---|---|
Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Staging; Pemetrexed; Platinum; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2008 |
[A meta-analysis of pemetrexed plus platinum chemotherapy versus gemcitabine plus platinum chemotherapy for advanced non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Platinum; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2011 |
Problems involved in the clinical trials for non-small cell lung carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Mutation; Patient Selection; Pemetrexed; Platinum; Quinazolines | 2012 |
Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asia; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum; Survival Analysis; Treatment Outcome | 2013 |
Pemetrexed With Platinum Combination as a Backbone for Targeted Therapy in Non-Small-Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Platinum | 2016 |
Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcinoma: A Case Report and Review of Literature.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Platinum; Quinazolines; Small Cell Lung Carcinoma | 2016 |
Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Lung Neoplasms; Pemetrexed; Platinum; Retrospective Studies; Treatment Outcome | 2017 |
A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Female; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Pemetrexed; Platinum; Progression-Free Survival; Treatment Outcome | 2018 |
Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published Cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asbestos; Environmental Exposure; Heart Neoplasms; Humans; Neoplasms, Mesothelial; Pemetrexed; Pericardium; Platinum; Risk Factors; Survival Analysis; Treatment Outcome | 2019 |
Overall Survival and Safety With Pemetrexed/Platinum ± Anti-VEGF Followed by Pemetrexed ± Anti-VEGF Maintenance in Advanced Nonsquamous Non-Small-Cell Lung Cancer: A Pooled Analysis of 4 Randomized Studies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Pemetrexed; Platinum | 2022 |
A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immunotherapy; Lung Neoplasms; Network Meta-Analysis; Pemetrexed; Platinum | 2023 |
Continuation of osimertinib in EGFR-mutant non-small-cell lung cancer patients bearing CNS metastasis (EPONA study).
Topics: Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Pemetrexed; Platinum; Protein Kinase Inhibitors | 2023 |
27 trial(s) available for platinum and pemetrexed
| Article | Year |
|---|---|
Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Squamous Cell; Cisplatin; Cross-Over Studies; Dietary Supplements; Female; Glutamates; Guanine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Platinum; Prognosis; Treatment Outcome | 2009 |
Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dietary Supplements; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Pemetrexed; Platinum; Pleural Neoplasms; Vitamins | 2009 |
Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Platinum; Prospective Studies; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2011 |
[Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pemetrexed; Platinum; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Salvage Therapy; Taxoids; Treatment Failure | 2010 |
Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rat
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glutamates; Guanine; Humans; International Agencies; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Platinum; Quality of Life; Quinazolines; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2011 |
Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asia; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum; Survival Analysis; Treatment Outcome | 2013 |
Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Niacinamide; Pemetrexed; Phenylurea Compounds; Platinum; Pleural Neoplasms; Prognosis; Protein Kinase Inhibitors; Salvage Therapy; Sorafenib; Survival Rate | 2013 |
Phase II study on Javanica oil emulsion injection (Yadanzi®) combined with chemotherapy in treating patients with advanced lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brucea; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Emulsions; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Phytotherapy; Plant Oils; Platinum; Prognosis | 2013 |
Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Pemetrexed; Platinum; Protein Kinase Inhibitors; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome | 2015 |
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Piperazines; Platinum; Young Adult | 2017 |
Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Anemia; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Piperazines; Platinum; Protein Kinase Inhibitors; Young Adult | 2018 |
EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Selection; Pemetrexed; Platinum; Progression-Free Survival; Prospective Studies; Retrospective Studies | 2018 |
Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pemetrexed; Platinum; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate | 2019 |
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Platinum | 2020 |
A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Humans; Lung Neoplasms; Pemetrexed; Platinum | 2020 |
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Humans; Lung Neoplasms; Pemetrexed; Platinum | 2020 |
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
Topics: Acrylamides; Adult; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Pemetrexed; Platinum; Protein Kinase Inhibitors; Survival Analysis | 2020 |
A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801).
Topics: Acrylamides; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Pemetrexed; Platinum; Progression-Free Survival; Safety; Treatment Outcome | 2021 |
Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Pemetrexed; Platinum | 2021 |
Study Design and Rationale for Espera Trial: A Multicentre, Randomized, Phase II Clinical Trial Evaluating the Potential Efficacy of Adding SBRT to Pembrolizumab-Pemetrexed Maintenance in Responsive or Stable Advanced Non-Squamous NSCLC After Chemo-Immuno
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Immunotherapy; Lung Neoplasms; Pemetrexed; Platinum; Radiosurgery; Tumor Microenvironment | 2022 |
Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed-Platinum-Radiation in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer: Results of a Phase I Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA Repair; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Platinum | 2022 |
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Pemetrexed; Platinum; Receptor Protein-Tyrosine Kinases | 2022 |
Results from the IMpower132 China cohort: Atezolizumab plus platinum-based chemotherapy in advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Humans; Lung Neoplasms; Pemetrexed; Platinum | 2023 |
Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pemetrexed; Platinum; Pleural Neoplasms | 2022 |
Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Pemetrexed; Platinum; Protein-Tyrosine Kinases; Proto-Oncogene Proteins | 2023 |
Rationale and Design of the Phase II ANTELOPE Study of Atezolizumab, Carboplatin and nab-Paclitaxel vs. Pembrolizumab, Platinum and Pemetrexed in TTF-1 Negative, Metastatic Lung Adenocarcinoma (AIO-TRK-0122).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Pemetrexed; Platinum; Retrospective Studies; Thyroid Nuclear Factor 1 | 2023 |
ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment.
Topics: Carboplatin; Cisplatin; Humans; Mesothelioma, Malignant; Pemetrexed; Platinum; Tumor Microenvironment | 2023 |
61 other study(ies) available for platinum and pemetrexed
| Article | Year |
|---|---|
Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum; Retrospective Studies; Treatment Outcome | 2009 |
Pemetrexed re-challenge in pleural malignant mesothelioma: an option for a subset of patients initially treated with pemetrexed-platinum doublets in the first-line setting?
Topics: Antineoplastic Agents; Glutamates; Guanine; Humans; Mesothelioma; Pemetrexed; Platinum; Pleural Neoplasms | 2011 |
[Effect of pemetrexed plus platinum for chemotherapy-naive advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum; Retrospective Studies; Thymidylate Synthase; Treatment Outcome; Young Adult | 2012 |
Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma.
Topics: 5'-Nucleotidase; Adult; Antineoplastic Agents; Biopsy; Cell Adhesion; Cohort Studies; DNA Repair; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Genome-Wide Association Study; Glutamates; Guanine; Humans; Immunohistochemistry; Mesothelioma; Oligonucleotide Array Sequence Analysis; Pemetrexed; Platinum; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Advanced non-small cell lung cancer (NSCLC): maintenance therapy for all?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Induction Chemotherapy; Lung Neoplasms; Neoplasm Staging; Pemetrexed; Platinum; Quinazolines | 2012 |
Secondline chemotherapy versus best supportive care in patient with malignant pleural mesothelioma: a retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Neoplasm Staging; Palliative Care; Pemetrexed; Platinum; Pleural Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Female; Glutamates; Guanine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Observational Studies as Topic; Pemetrexed; Platinum; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; United States | 2013 |
[Efficacy of chemotherapy after EGFR-TKIs resistance in 191 patients with Unknow EGFR gene mutation in advanced lung adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; ErbB Receptors; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Platinum; Protein Kinase Inhibitors; Retrospective Studies; Survival Rate | 2013 |
Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Endonucleases; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Pemetrexed; Platinum; Polymorphism, Single Nucleotide; Proportional Hazards Models; Retrospective Studies; Thymidylate Synthase | 2014 |
PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carrier Proteins; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Membrane Proteins; Middle Aged; Neoplasm Staging; Pemetrexed; Platinum; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2014 |
Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Glutamates; Guanine; Humans; Male; Mesothelioma; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Mutagenesis, Insertional; Pemetrexed; Pharmacogenetics; Platinum; Pleural Neoplasms; Polymorphism, Genetic; Prognosis; Retrospective Studies; Survival Analysis; Tandem Repeat Sequences; Thymidylate Synthase; Treatment Outcome | 2014 |
The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Platinum; Vascular Endothelial Growth Factor A | 2015 |
Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Platinum; Protein Kinase Inhibitors; Retrospective Studies; Treatment Failure | 2015 |
The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.
Topics: Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pemetrexed; Platinum; Prognosis; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2015 |
Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Cell Adhesion Molecules; Cell Line, Tumor; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Disease-Free Survival; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Nestin; Pemetrexed; Platinum; Pleural Neoplasms; Pneumonectomy; Prognosis; Sarcoma; Stem Cell Factor | 2015 |
Health-related quality of life after first-line anti-cancer treatments for advanced non-small cell lung cancer in clinical practice.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum; Prospective Studies; Quality of Life; Quinazolines; Sickness Impact Profile; Surveys and Questionnaires; World Health Organization | 2016 |
Osimertinib improves progression-free survival in NSCLC.
Topics: Acrylamides; Aniline Compounds; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Pemetrexed; Platinum; Progression-Free Survival; Protein Kinase Inhibitors | 2017 |
Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Neutropenia; Pemetrexed; Platinum; Retrospective Studies; Taxoids | 2017 |
Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Carboplatin; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Mass Spectrometry; Middle Aged; Pemetrexed; Peptides; Platinum; Retrospective Studies; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2017 |
Prognostic value of pretreatment inflammatory biomarkers in advanced lung adenocarcinoma patients receiving first-line pemetrexed/platinum doublet.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Disease-Free Survival; Female; Humans; Inflammation; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Monocytes; Neutrophils; Pemetrexed; Platelet Count; Platinum; Prognosis | 2017 |
Practice Patterns and Outcomes for Pemetrexed Plus Platinum Doublet as Neoadjuvant Chemotherapy in Adenocarcinomas of Lung: Looking Beyond the Usual Paradigm.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Pemetrexed; Platinum; Young Adult | 2018 |
Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment.
Topics: Adult; Aged; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum; Prognosis; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Survival Rate; Young Adult | 2018 |
Comparing first-line treatment patterns and clinical outcomes of patients with pan-negative advanced non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Platinum; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinorelbine | 2018 |
Immunotherapy in patients who have NSCLC without EGFR or ALK mutations.
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Design; ErbB Receptors; Humans; Lung Neoplasms; Molecular Targeted Therapy; Multicenter Studies as Topic; Pemetrexed; Platinum; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Treatment Outcome | 2018 |
Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Latin America; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pemetrexed; Platinum; Pleural Neoplasms; Progression-Free Survival; Thoracic Surgical Procedures | 2019 |
Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Genetic Variation; Genomics; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Palliative Care; Pemetrexed; Peritoneal Neoplasms; Platinum; Treatment Outcome; Young Adult | 2019 |
[Association between the HER2 Gene Status and the Efficacy of First-line Pemetrexed Combined with Platinum Chemotherapy in Patients with Advanced Lung
Adenocarcinoma].
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Genes, erbB-2; Humans; Male; Middle Aged; Mutation; Pemetrexed; Platinum; Retrospective Studies; Treatment Outcome | 2019 |
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Platinum; Progression-Free Survival; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Survival Rate; Young Adult | 2020 |
Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors.
Topics: Drug Therapy, Combination; Family Characteristics; Humans; Lung Neoplasms; Pemetrexed; Platinum; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Retrospective Studies | 2020 |
Is Gefitinib Combined With Platinum-Doublet Chemotherapy a Counterpart to Osimertinib Monotherapy in Advanced
Topics: Acrylamides; Aniline Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Pemetrexed; Platinum | 2020 |
Clinical factors associated with treatment toxicity of pemetrexed plus platinum in elderly patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Pemetrexed; Platinum; Treatment Outcome | 2020 |
Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum-pemetrexed: The first report of two cases.
Topics: Biomarkers, Tumor; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Muscle Tissue; Pemetrexed; Platinum | 2020 |
Anlotinib or platinum-pemetrexed as second-line therapy in EGFR T790M-negative lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Mutation; Pemetrexed; Platinum; Protein Kinase Inhibitors; Quinolines; Retrospective Studies | 2020 |
Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non-small-cell lung cancer in China.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Humans; Lung Neoplasms; Pemetrexed; Platinum | 2022 |
Another Brick in the Wall: Sintilimab Plus Chemotherapy in Advanced Lung Cancer.
Topics: Antibodies, Monoclonal, Humanized; Double-Blind Method; Humans; Lung Neoplasms; Pemetrexed; Platinum | 2020 |
Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leukopenia; Male; Mesothelioma, Malignant; Middle Aged; Neutropenia; Pemetrexed; Platinum; Progression-Free Survival; Retrospective Studies; Thrombocytopenia | 2021 |
Comparing Immunotherapies in Combination With Chemotherapy for Previously Untreated Advanced Nonsquamous NSCLC.
Topics: Antibodies, Monoclonal, Humanized; Double-Blind Method; Humans; Immunotherapy; Lung Neoplasms; Pemetrexed; Platinum | 2020 |
Response to Letter to the Editor: Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: A Randomized, Double-Blind, Phase 3 Study (ORIENT-11).
Topics: Antibodies, Monoclonal, Humanized; Double-Blind Method; Humans; Lung Neoplasms; Pemetrexed; Platinum | 2020 |
Combination of Chemotherapy and ALK Inhibitors in ALK-Positive NSCLC.
Topics: Drug Therapy, Combination; Humans; Lung Neoplasms; Pemetrexed; Platinum; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases | 2021 |
Effect of renin-angiotensin system inhibitors on pemetrexed plus platinum-induced hematological toxicities: a multicenter retrospective study using three propensity score analyses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Pemetrexed; Platinum; Propensity Score; Renin-Angiotensin System; Retrospective Studies | 2021 |
Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Humans; Lung Neoplasms; Pemetrexed; Platinum | 2021 |
Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Diabetes Complications; Diabetes Mellitus; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Metformin; Middle Aged; Mutation; Pemetrexed; Platinum; Probability; Proportional Hazards Models; Retrospective Studies; Taiwan; Treatment Outcome | 2021 |
Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results-Medicare data.
Topics: Aged; Female; Humans; Male; Medicare; Mesothelioma; Mesothelioma, Malignant; Pemetrexed; Platinum; Pleural Neoplasms; Retrospective Studies; United States | 2022 |
Topics: Adenocarcinoma; Biomarkers; Case-Control Studies; Genotype; Humans; India; Methylenetetrahydrofolate Reductase (NADPH2); Pemetrexed; Platinum; Polymorphism, Genetic | 2022 |
[Analysis of the Efficacy of Pemetrexed Maintenance Therapy in Patients with
Malignant Pleural Mesothelioma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Neutropenia; Pemetrexed; Platinum; Pleural Neoplasms | 2022 |
Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell lung cancer: a retrospective analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Pemetrexed; Platinum; Retrospective Studies; Treatment Outcome | 2022 |
The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer.
Topics: Bevacizumab; Carcinoma, Non-Small-Cell Lung; China; ErbB Receptors; Humans; Immune Checkpoint Inhibitors; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; Mutation; NF-E2-Related Factor 2; Pemetrexed; Platinum; Prevalence; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Taxoids | 2022 |
Clinical efficacy and safety of pemetrexed with or without either Bevacizumab or Pembrolizumab in patients with metastatic nonsquamous non-small cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Humans; Lung Neoplasms; Pemetrexed; Platinum; Retrospective Studies; Treatment Outcome | 2023 |
BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Humans; Immunohistochemistry; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Pemetrexed; Platinum; Pleural Neoplasms; Tumor Suppressor Proteins; Ubiquitin Thiolesterase | 2022 |
Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Pemetrexed; Platinum; Retrospective Studies | 2022 |
Real-world treatment pattern and comprehensive comparative effectiveness of Endostar plus different chemotherapy in advanced patients with non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Endostatins; Humans; Lung Neoplasms; Pemetrexed; Platinum; Recombinant Proteins | 2022 |
Prognostic factors of malignant peritoneal mesothelioma: a retrospective study of 52 female patients.
Topics: Female; Humans; Ki-67 Antigen; Mesothelioma, Malignant; Paclitaxel; Pemetrexed; Peritoneal Neoplasms; Platinum; Prognosis; Retrospective Studies | 2022 |
Computed Tomography Image under Artificial Intelligence Algorithm to Evaluate the Nursing and Treatment Effect of Pemetrexed Combined Platinum-Based Chemotherapy on Elderly Lung Cancer.
Topics: Aged; Antigens, Neoplasm; Artificial Intelligence; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Keratin-19; Lung Neoplasms; Pemetrexed; Platinum; Tomography; Tomography, X-Ray Computed | 2022 |
Pembrolizumab for the better treatment of EGFR-mutant T790M-negative advanced lung adenocarcinoma patients than dual treatment of pemetrexed plus platinum after tyrosine kinase inhibitor treatment failure.
Topics: Adenocarcinoma of Lung; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Pemetrexed; Platinum; Prospective Studies; Protein Kinase Inhibitors; Treatment Failure | 2022 |
Does Molecular Profiling of
Topics: B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Pemetrexed; Platinum; Proto-Oncogene Proteins p21(ras) | 2022 |
What's Current and What's New in Mesothelioma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Pemetrexed; Platinum; Pleural Neoplasms | 2022 |
A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Disease Progression; Humans; Lung Neoplasms; Pemetrexed; Platinum; Proto-Oncogene Proteins p21(ras) | 2022 |
Lorlatinib beyond progression plus platinum/pemetrexed for ALK-positive non-small cell lung cancer patients: report of two cases.
Topics: Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Humans; Lactams, Macrocyclic; Lung Neoplasms; Pemetrexed; Platinum; Protein Kinase Inhibitors | 2023 |
The Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Endonucleases; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Pemetrexed; Platinum; Prospective Studies; Thymidylate Synthase; Treatment Outcome | 2023 |
Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non-Small Cell Lung Cancer: The Piedmont Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Folic Acid Antagonists; Humans; Lung Neoplasms; Pemetrexed; Platinum; Retrospective Studies | 2023 |
Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland.
Topics: Bevacizumab; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Humans; Ipilimumab; Mesothelioma, Malignant; Nivolumab; Pemetrexed; Platinum; Switzerland | 2023 |